CO2022008675A2 - Derivados bicíclicos sustituidos de piperidina útiles como activadores de células t - Google Patents

Derivados bicíclicos sustituidos de piperidina útiles como activadores de células t

Info

Publication number
CO2022008675A2
CO2022008675A2 CONC2022/0008675A CO2022008675A CO2022008675A2 CO 2022008675 A2 CO2022008675 A2 CO 2022008675A2 CO 2022008675 A CO2022008675 A CO 2022008675A CO 2022008675 A2 CO2022008675 A2 CO 2022008675A2
Authority
CO
Colombia
Prior art keywords
derivatives useful
substituted piperidine
piperidine derivatives
cell activators
compounds
Prior art date
Application number
CONC2022/0008675A
Other languages
English (en)
Inventor
Upender Velaparthi
Min Ding
Robert G Gentles
Scott W Martin
Richard E Olson
Saumya Roy
Prasada Rao Jalagam
Jayakumar Sankara Warrier
Louis CHUPAK
Denise Grunenfelder
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CO2022008675A2 publication Critical patent/CO2022008675A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se describen los compuestos de la Fórmula (I): (I) o una sal del mismo, en donde: X es CR6 o N; Y es CR3 o N; R1, R2, R3, R4, R5, R6, R7, y m son como se definen en la presente. También se describen métodos para usar tales compuestos para inhibir la actividad de uno o ambos de diacilglicerol quinasa alfa (DGK ) y diacilglicerol quinasa zeta (DGK), y composiciones farmacéuticas que comprenden tales compuestos. Estos compuestos son útiles en el tratamiento de infecciones virales y trastornos proliferativos, como el cáncer.
CONC2022/0008675A 2019-12-23 2022-06-22 Derivados bicíclicos sustituidos de piperidina útiles como activadores de células t CO2022008675A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201911053552 2019-12-23
PCT/US2020/066507 WO2021133750A1 (en) 2019-12-23 2020-12-22 Substituted bicyclic piperidine derivatives useful as t cell activators

Publications (1)

Publication Number Publication Date
CO2022008675A2 true CO2022008675A2 (es) 2022-07-19

Family

ID=74191945

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0008675A CO2022008675A2 (es) 2019-12-23 2022-06-22 Derivados bicíclicos sustituidos de piperidina útiles como activadores de células t

Country Status (15)

Country Link
US (1) US11964973B2 (es)
EP (1) EP4081523A1 (es)
JP (1) JP2023508052A (es)
KR (1) KR20220119455A (es)
CN (1) CN114901660A (es)
AR (1) AR120823A1 (es)
AU (1) AU2020412615A1 (es)
BR (1) BR112022012195A2 (es)
CA (1) CA3163013A1 (es)
CL (1) CL2022001710A1 (es)
CO (1) CO2022008675A2 (es)
IL (1) IL294272A (es)
MX (1) MX2022007842A (es)
PE (1) PE20221487A1 (es)
WO (1) WO2021133750A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022012625A2 (pt) 2019-12-24 2022-09-06 Carna Biosciences Inc Compostos moduladores de diacilglicerol quinase
CN117396478A (zh) 2021-06-23 2024-01-12 吉利德科学公司 二酰基甘油激酶调节化合物
AU2022299051A1 (en) 2021-06-23 2023-12-07 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CR20230585A (es) 2021-06-23 2024-02-19 Gilead Sciences Inc Compuestos Moduladores de Diacilglicerol Quinasa.
WO2023122778A1 (en) * 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Pyridazinone derivatives useful as t cell activators
WO2023150186A1 (en) * 2022-02-01 2023-08-10 Arvinas Operations, Inc. Dgk targeting compounds and uses thereof
WO2023165525A1 (en) * 2022-03-01 2023-09-07 Insilico Medicine Ip Limited Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof
WO2023184327A1 (en) * 2022-03-31 2023-10-05 InventisBio Co., Ltd. Kinase inhibitors, preparation methods and uses thereof

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4324893A (en) 1979-04-18 1982-04-13 American Home Products Corporation 4-Amino-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives
MY140679A (en) 2001-05-24 2010-01-15 Avanir Pharmaceuticals Inhibitors of macrohage migration inhibitory factor and methods for identifying the same
BR0312204A (pt) 2002-06-27 2005-04-26 Schering Ag Antagonista de receptor ccr5 de quinolina substituìda
GB0230018D0 (en) 2002-12-23 2003-01-29 Syngenta Ltd Fungicides
TW200418829A (en) 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
TWI289141B (en) 2003-03-11 2007-11-01 Hoffmann La Roche F. Ag. Quinolinone derivatives and uses thereof
WO2004087880A2 (en) 2003-03-26 2004-10-14 Bayer Pharmaceuticals Corporation Compounds and their use to treat diabetes and related disorders
GB0316915D0 (en) 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
BRPI0412876A (pt) 2003-07-22 2006-10-03 Janssen Pharmaceutica Nv derivados de quinolinona como inibidores de c-fms quinase
MXJL06000006A (es) 2003-08-22 2006-05-04 Avanir Pharmaceuticals Derivados de naftiridina sustituidos como inhibidores del factor inhibidor de la migracion de macrofagos y su uso en el tratamiento de enfermedades en el hombre.
US7381401B2 (en) 2004-01-08 2008-06-03 The University Of Chicago T cell anergy is reversed by active Ras and regulated by diacylglycerol kinase
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
WO2006105021A2 (en) 2005-03-25 2006-10-05 Tolerrx, Inc. Gitr binding molecules and uses therefor
US8034953B2 (en) 2005-05-10 2011-10-11 Incyte Corporation Modulators of indoleamine 2,3-dioxygenase and methods of using the same
CA3201163A1 (en) 2005-07-01 2007-01-11 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
ES2540561T3 (es) 2005-12-20 2015-07-10 Incyte Corporation N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa
GB0605689D0 (en) 2006-03-21 2006-05-03 Novartis Ag Organic compounds
JP2007308402A (ja) 2006-05-17 2007-11-29 Sumitomo Chemical Co Ltd シンナモイル化合物及びその用途
JP2007308441A (ja) 2006-05-22 2007-11-29 Sumitomo Chemical Co Ltd 含複素環化合物及びその用途
JP5319532B2 (ja) 2006-09-19 2013-10-16 インサイト・コーポレイション インドールアミン２，３−ジオキシゲナーゼのモジュレーターとしてのｎ−ヒドロキシアミジノヘテロサイクル
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
AU2007301958A1 (en) 2006-09-29 2008-04-03 Tibotec Pharmaceuticals Ltd. Quinolinone derivatives
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
AU2008275589B2 (en) 2007-07-12 2013-11-21 Gitr, Inc. Combination therapies employing GITR binding molecules
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
US10047066B2 (en) 2007-11-30 2018-08-14 Newlink Genetics Corporation IDO inhibitors
EP2296789A1 (fr) 2008-05-29 2011-03-23 Saint-Gobain Centre de Recherches et d'Etudes Européen Structure en nid d'abeille a base de titanate d'aluminium
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
WO2010042489A2 (en) 2008-10-06 2010-04-15 Emory University Aminoquinoline derived heat shock protein 90 inhibitors, methods of preparing same, and methods for their use
HRP20240240T1 (hr) 2008-12-09 2024-04-26 F. Hoffmann - La Roche Ag Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice
WO2010088408A2 (en) 2009-01-28 2010-08-05 Emory University Subunit selective nmda receptor antagonists for the treatment of neurological conditions
AU2010289677B2 (en) 2009-09-03 2014-07-31 Merck Sharp & Dohme Llc Anti-GITR antibodies
CA2778115C (en) 2009-10-28 2016-04-05 Newlink Genetics Corporation Imidazole derivatives as ido inhibitors
ES2557454T3 (es) 2009-12-10 2016-01-26 F. Hoffmann-La Roche Ag Anticuerpos que se unen al dominio extracelular 4 de CSF1R humana y su utilización
PE20170779A1 (es) 2010-03-04 2017-07-04 Macrogenics Inc Anticuerpos reactivos con b7-h3, fragmentos inmunologicamente activos de los mismos y usos de los mismos
EP2542588A1 (en) 2010-03-05 2013-01-09 F. Hoffmann-La Roche AG Antibodies against human csf-1r and uses thereof
EP2542587A1 (en) 2010-03-05 2013-01-09 F. Hoffmann-La Roche AG Antibodies against human csf-1r and uses thereof
RS58211B1 (sr) 2010-05-04 2019-03-29 Five Prime Therapeutics Inc Antitela koja vezuju csf1r
WO2012009649A1 (en) 2010-07-16 2012-01-19 Anderson Gaweco Mif inhibitors and their uses
NZ729044A (en) 2010-09-09 2020-07-31 Pfizer 4-1bb binding molecules
EP2696682B1 (en) 2011-04-13 2018-03-21 Innovimmune Biotherapeutics, Inc. Mif inhibitors and their uses
NO2694640T3 (es) 2011-04-15 2018-03-17
RU2625034C2 (ru) 2011-04-20 2017-07-11 МЕДИММЬЮН, ЭлЭлСи Антитела и другие молекулы, которые связывают в7-н1 и pd-1
DK2785375T3 (da) 2011-11-28 2020-10-12 Merck Patent Gmbh Anti-pd-l1-antistoffer og anvendelser deraf
WO2013087699A1 (en) 2011-12-15 2013-06-20 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
WO2013119716A1 (en) 2012-02-06 2013-08-15 Genentech, Inc. Compositions and methods for using csf1r inhibitors
WO2013118071A1 (en) 2012-02-09 2013-08-15 Glenmark Pharmaceuticals S.A. BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
EP3539984A1 (en) 2012-05-11 2019-09-18 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
RU2718751C2 (ru) 2012-08-31 2020-04-14 Файв Прайм Терапьютикс, Инк. Способы лечения патологических состояний антителами, которые связываются с рецептором колониестимулирующего фактора 1 (csf1r)
WO2014039513A2 (en) 2012-09-04 2014-03-13 The Trustees Of The University Of Pennsylvania Inhibition of diacylglycerol kinase to augment adoptive t cell transfer
CN107849022A (zh) 2015-04-10 2018-03-27 亚瑞克西斯制药公司 取代的喹唑啉化合物和其使用方法
EP3889145B1 (en) 2015-12-17 2024-02-21 Merck Patent GmbH 8-cyano-5-piperidino-quinolines as tlr7/8 antagonists and their uses for treating immune disorders
US10946020B2 (en) 2016-04-06 2021-03-16 University Of Virginia Patent Foundation Compositions and methods for treating cancer
HUE056777T2 (hu) 2016-12-22 2022-03-28 Amgen Inc Benzizotiazol-, izotiazolo[3,4-b]piridin-, kinazolin-, ftálazin-, pirido[2,3-d]piridazin- és pirido[2,3-d]pirimidin-származékok mint KRAS G12C inhibitorok tüdõ-, hasnyálmirigy- vagy vastagbélrák kezelésére
GB201700814D0 (en) 2017-01-17 2017-03-01 Liverpool School Tropical Medicine Compounds
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
WO2019005883A1 (en) 2017-06-26 2019-01-03 University Of Virginia Patent Foundation COMPOSITIONS AND USES THEREOF
JP7347825B2 (ja) 2017-09-28 2023-09-20 薬捷安康（南京）科技股▲分▼有限公司 Ｐｄｅ９阻害剤及びその用途
HRP20230627T1 (hr) 2018-06-27 2023-09-29 Bristol-Myers Squibb Company Spojevi naftiridinona korisni kao aktivatori t ćelija
CA3104654A1 (en) 2018-06-27 2020-01-02 Bristol-Myers Squibb Company Substituted naphthyridinone compounds useful as t cell activators
AR119821A1 (es) 2019-08-28 2022-01-12 Bristol Myers Squibb Co Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
EP4065584A1 (en) 2019-11-28 2022-10-05 Bayer Aktiengesellschaft Substituted aminoquinolones as dgkalpha inhibitors for immune activation
KR20220122637A (ko) 2019-11-28 2022-09-02 바이엘 악티엔게젤샤프트 면역 활성화를 위한 dgk알파 억제제로서의 치환된 아미노퀴놀론
US20230062100A1 (en) 2019-11-28 2023-03-02 Bayer Aktiengesellschaft Substituted aminoquinolones as dgkalpha inhibitors for immune activation

Also Published As

Publication number Publication date
CN114901660A (zh) 2022-08-12
AR120823A1 (es) 2022-03-23
US11964973B2 (en) 2024-04-23
CL2022001710A1 (es) 2023-01-13
IL294272A (en) 2022-08-01
JP2023508052A (ja) 2023-02-28
KR20220119455A (ko) 2022-08-29
EP4081523A1 (en) 2022-11-02
CA3163013A1 (en) 2021-07-01
AU2020412615A1 (en) 2022-08-18
US20210188845A1 (en) 2021-06-24
MX2022007842A (es) 2022-07-19
WO2021133750A1 (en) 2021-07-01
BR112022012195A2 (pt) 2022-09-06
PE20221487A1 (es) 2022-09-26
TW202136254A (zh) 2021-10-01

Similar Documents

Publication Publication Date Title
CL2020003260A1 (es) Compuestos de naftiridinona sustituidos útiles como activadores de células t
CO2022008675A2 (es) Derivados bicíclicos sustituidos de piperidina útiles como activadores de células t
CO2022002424A2 (es) Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
BR112022012204A2 (pt) Compostos de heteroarila substituída úteis como ativadores de célula t
EA202190137A1 (ru) Нафтиридиноновые соединения для применения в качестве активаторов t-клеток
PE20190326A1 (es) Isoquinolin-3-il-carboxamidas y preparacion y uso de las mismas
BR112022012220A2 (pt) Compostos de piperazina quinolinonil substituída úteis como ativadores de célula t
PE20180117A1 (es) Inhibidores de indolamina-2,3-dioxigenasa para el tratamiento de cancer
BR112022012179A2 (pt) Compostos de quinazolina substituída úteis como ativadores de célula t
BR112022012222A2 (pt) Derivados de piperazina substituídos úteis como ativadores de células t
PE20181366A1 (es) Compuestos heterociclicos utiles como moduladores de factor de necrosis tumoral (tnf) alfa
PE20181297A1 (es) Dinucleotidos de purino ciclico como moduladores de sting
BR112017010882B8 (pt) Compostos de n-((het)-arilmetil)-heteroaril-carboxamidas como inibidores de calicreína plasmática e seus usos
AR102204A1 (es) Compuestos derivados de amino-alquilbenzotiazepinas
PE20171177A1 (es) Compuestos aminopirimidinilo inhibidores de jak
PE20130010A1 (es) Derivado de 1,3,4,8-tetrahidro-2h-pirido[1,2-a]pirazina como inhibidor de la integrasa del vih
SV2018005655A (es) "derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cancer"
PE20142452A1 (es) AMIDAS CICLICAS COMO INHIBIDORES DE MetAP-2
PE20141352A1 (es) Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento
CL2019000662A1 (es) Inhibidores de dopamina–b–hidroxilasa.
PE20180355A1 (es) Desacetoxitubulisina h y analogos de esta
CL2021001656A1 (es) Compuestos de imidazopiridina e imidazopiridina y sus usos.
CO2020010306A2 (es) Compuestos de sulfonimidoilpurinona 7-sustituida y derivados para el tratamiento y profilaxis de cáncer de hígado.
DOP2019000119A (es) Moduladores de ROR gamma (RORy)
CO2023013321A2 (es) Compuestos de oxoisoindolina sustituidos con piridinilo